Loading…
Loading…
GRAL does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GRAL and 80,000+ other tickers.
See exactly how GRAL's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GRAL and 80,000+ other tickers.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted…
Grail, Inc. (GRAL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire BEN
BENSALEM, Pa., July 22, 2026 /PRNewswire/ -- The Law Offices of Howard G.
Deadline Alert: GRAL Investors Who Lost Money After Grail's NHS-Galleri Trial Failed Its Primary Endpoint Have Until August 4, 2026 to Seek Lead Plaintiff Appointment in Securities Class Action NEW YORK, July 22, 2026 /PRNewswire/ -- IMPORTANT DATE: August 4, 2026. Investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025 and February 19, 2026 and wish to seek appointment as lead plaintiff must file a motion by this date.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds GRAIL, Inc. (“GRAIL” or the “Company”) (NASDAQ: GRAL) investors of the August 4, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The GRAIL Class Action Lawsuit : Do you, or did you, own shares of GRAIL, Inc. (NASDAQ: GRAL)?
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in GRAIL, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/grail-class-action-lawsuit.